

wherein x is 1, 2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

R¹ is H or lower alkyl;

X is N;

R² is H, alkyl, alkoxy, halogen, amino or substituted amino;


R^{2a}, R^{2b} and R^{2c} are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

R³ is H, alkyl, arylalkyl, aryloxy carbonyl, alkyl oxy carbonyl, alkynyl oxy carbonyl, alkenyl oxy carbonyl, aryl carbonyl, alkyl carbonyl, aryl, heteroaryl, alkyl(halo) aryloxy carbonyl, alkyloxy(halo) aryloxy carbonyl, cycloalkyl aryloxy carbonyl, cycloalkyloxy aryloxy carbonyl, cycloheteroalkyl, heteroaryl carbonyl, heteroaryl-heteroaryl alkyl, alkyl carbonyl amino, aryl carbonyl amino, heteroaryl carbonyl amino, alkoxy carbonyl amino, aryloxy carbonyl amino, heteroaryl oxy carbonyl amino, heteroaryl-heteroaryl carbonyl, alkyl sulfonyl, alkenyl sulfonyl, heteroaryl oxy carbonyl, cycloheteroalkyl oxy carbonyl, heteroaryl alkyl, aminocarbonyl, substituted aminocarbonyl, alkyl aminocarbonyl, aryl aminocarbonyl, heteroaryl alkenyl, cycloheteroalkyl heteroaryl alkyl, hydroxy alkyl, alkoxy, alkoxy aryloxy carbonyl, aryl alkyl oxy carbonyl, alkyl aryloxy carbonyl, aryl heteroaryl alkyl, aryl alkyl aryl alkyl, aryloxy aryl alkyl, alkynyl oxy carbonyl, haloalkoxy aryloxy carbonyl, alkoxy carbonyl aryloxy carbonyl, aryloxy aryloxy carbonyl, aryl sulfinyl aryl carbonyl, aryl thio aryl carbonyl, aryl alkenyl oxy carbonyl, heteroaryl oxy aryl alkyl, aryloxy aryl carbonyl, aryloxy aryl alkyl oxy carbonyl, aryl alkyl carbonyl, aryloxy alkyl oxy carbonyl, aryl alkyl sulfonyl, aryl thio carbonyl, aryl alkenyl sulfonyl, heteroaryl sulfonyl, aryl sulfonyl, alkoxy aryl alkyl, heteroaryl alkoxy carbonyl, aryl heteroaryl alkyl, alkoxy aryl carbonyl, aryloxy heteroaryl alkyl, heteroaryl alkyl oxy aryl alkyl, aryl aryl alkyl, aryl alkenyl aryl alkyl, aryl alkoxy aryl alkyl, aryl carbonyl aryl alkyl, alkyl aryloxy aryl alkyl, aryl alkoxy carbonyl heteroaryl alkyl, heteroaryl aryl alkyl, aryl carbonyl heteroaryl alkyl, heteroaryl oxy aryl alkyl, aryl alkenyl heteroaryl alkyl, aryl amino aryl alkyl, aminocarbonyl aryl aryl alkyl or polyhaloalkyl aryloxy carbonyl;


Y is CO₂R⁴ where R⁴ is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure P(O)(OR^{4a})R⁵ where R^{4a} is H or a prodrug ester, R⁵ is alkyl or aryl or a phosphonic acid of the structure P(O)(OR^{4a})₂ where R^{4a} is H or a prodrug ester;

or stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof. --

--2. (Amended) The compound as defined in Claim 1 having the structure




or




--10. (Amended) The compound as defined in Claim 1 wherein

$(CH_2)_x$ is CH_2 , $(CH_2)_2$, $(CH_2)_3$, or $\begin{array}{c} CH_3 \\ | \\ CH \\ | \\ CH_3 \end{array}$, $(CH_2)_m$ is CH_2 , or $\begin{array}{c} R_a \\ | \\ CH \end{array}$ where R_a is alkyl or alkenyl, $(CH_2)_n$ is CH_2 , R^1 is lower alkyl, R^2 is H, R^{2a} is H, R^4 is H, X is CH, and R^3 is arylalkyloxycarbonyl, arylheteroarylalkyl, aryloxyarylalkyl, arylalkyl, aryloxycarbonyl, haloaryl-oxycarbonyl, alkoxyaryloxycarbonyl, alkylaryloxycarbonyl, aryloxyaryloxycarbonyl, heteroaryloxyarylalkyl, heteroaryloxycarbonyl, aryloxyarylcarbonyl, arylalkenyloxycarbonyl, cycloalkylaryloxycarbonyl, arylalkylarylcarbonyl, heteroaryl-heteroarylalkyl, cycloalkyloxyaryloxycarbonyl, heteroaryl-heteroarylcarbonyl, alkyloxyaryloxycarbonyl, arylalkylsulfonyl, arylalkenylsulfonyl, alkoxyarylalkyl, arylthiocarbonyl, cycloheteroalkylalkyloxycarbonyl, cycloheteroalkyloxycarbonyl, or polyhaloalkylaryloxycarbonyl, which may be optionally substituted. --

--14. (Amended) The compound as defined in Claim 1 having the structure




--15. (Amended) The compound as defined in Claim 1 having the structure



where $(CH_2)_n$ is CH_2 or $\begin{array}{c} CH_3 \\ | \\ CH \end{array}$ --

--17. (Amended) The compound as defined in Claim 1 having the structure



--34. (Amended) A method for lowering blood glucose levels or for treating diabetes or for treating a premalignant disease, an early malignant disease, a malignant disease, or a dysplastic disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1. --

[illegible]

an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan;
amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, carvedilol, or
clonidine HCl; the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole or
ifetroban. --

11